Comment on "Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab".
作者信息
Abdelmaksoud Ayman, Goldust Mohamad, Vestita Michelangelo
机构信息
Mansoura Dermatology, Venerology and Leprology Hospital, Mansoura, Egypt.
Department of Dermatology, University of Rome G. Marconi, Rome, Italy.
出版信息
Int J Dermatol. 2020 Nov;59(11):1417-1418. doi: 10.1111/ijd.15215. Epub 2020 Sep 29.
Abstract
摘要
相似文献
1
Comment on "Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab".关于“一名新冠肺炎患者慢性自发性荨麻疹加重：对奥马珠单抗迅速且显著的反应”的评论
Int J Dermatol. 2020 Nov;59(11):1417-1418. doi: 10.1111/ijd.15215. Epub 2020 Sep 29.
2
Safely use of omalizumab during SARS-CoV-2 infection in patients with chronic spontaneous urticaria.慢性自发性荨麻疹患者在感染SARS-CoV-2期间安全使用奥马珠单抗。
J Cosmet Dermatol. 2023 Jan;22(1):26-27. doi: 10.1111/jocd.15544. Epub 2022 Nov 30.
3
Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort Study.接受奥马珠单抗治疗的慢性特发性荨麻疹和哮喘患者中新型冠状病毒肺炎的发病率：一项多中心回顾性队列研究
J Cutan Med Surg. 2022 May-Jun;26(3):319-320. doi: 10.1177/12034754211049707. Epub 2021 Sep 29.
4
Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.奥马珠单抗对慢性自发性荨麻疹合并多种慢性诱导性荨麻疹患者有效。
Eur Ann Allergy Clin Immunol. 2021 Mar;53(2):91-93. doi: 10.23822/EurAnnACI.1764-1489.153. Epub 2021 Mar 1.
5
Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19.奥马珠单抗治疗慢性自发性荨麻疹合并新型冠状病毒肺炎患者的安全性
Dermatol Ther. 2021 Nov;34(6):e15111. doi: 10.1111/dth.15111. Epub 2021 Aug 31.
6
Omalizumab re-treatment rates in chronic spontaneous urticaria.奥马珠单抗在慢性自发性荨麻疹中的再治疗率。
Eur Ann Allergy Clin Immunol. 2020 May;52(4):187-189. doi: 10.23822/EurAnnACI.1764-1489.145. Epub 2020 May 7.
7
Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab.1例新型冠状病毒肺炎患者慢性自发性荨麻疹加重：对奥马珠单抗反应迅速且效果良好
Int J Dermatol. 2020 Oct;59(10):1294-1295. doi: 10.1111/ijd.15134. Epub 2020 Aug 17.
8
A very low number of circulating basophils is predictive of a poor response to omalizumab in chronic spontaneous urticaria.循环嗜碱性粒细胞数量极低预示着慢性自发性荨麻疹患者对奥马珠单抗治疗反应不佳。
Allergy. 2021 Apr;76(4):1254-1257. doi: 10.1111/all.14577. Epub 2020 Sep 17.
9
Comment on ''how does omalizumab affect the immunoinflammatory response in patients with chronic spontaneous urticaria?'': reply from author.关于《奥马珠单抗如何影响慢性自发性荨麻疹患者的免疫炎症反应？》的评论：作者回复
Cutan Ocul Toxicol. 2020 Mar;39(1):73. doi: 10.1080/15569527.2019.1710181. Epub 2020 Jan 12.
10
[HOW PERIPHERAL BASOPHILS IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA ARE CHANGED WITH OMALIZUMAB TREATMENT?].[慢性自发性荨麻疹患者外周嗜碱性粒细胞经奥马珠单抗治疗后有何变化？]
Arerugi. 2021;70(9):1196-1199. doi: 10.15036/arerugi.70.1196.
引用本文的文献
1
Omalizumab may protect allergic patients against COVID-19: A systematic review.奥马珠单抗可能保护过敏患者预防新型冠状病毒肺炎：一项系统评价。
World Allergy Organ J. 2023 Feb;16(2):100741. doi: 10.1016/j.waojou.2023.100741. Epub 2023 Jan 9.
2
The effect of COVID-19 on patients recieving omalizumab treatment.2019冠状病毒病对接受奥马珠单抗治疗患者的影响。
Rev Fr Allergol (2009). 2023 Mar;63(2):103281. doi: 10.1016/j.reval.2023.103281. Epub 2023 Jan 5.
3
Safely use of omalizumab during SARS-CoV-2 infection in patients with chronic spontaneous urticaria.慢性自发性荨麻疹患者在感染SARS-CoV-2期间安全使用奥马珠单抗。
J Cosmet Dermatol. 2023 Jan;22(1):26-27. doi: 10.1111/jocd.15544. Epub 2022 Nov 30.
4
The course of COVID-19 in patients with chronic spontaneous urticaria receiving omalizumab treatment.接受奥马珠单抗治疗的慢性自发性荨麻疹患者的新型冠状病毒肺炎病程
Rev Fr Allergol (2009). 2022 Dec;62(8):684-688. doi: 10.1016/j.reval.2022.06.003. Epub 2022 Jun 13.
5
COVID-19 Disease Leading to Chronic Spontaneous Urticaria Exacerbation: A Romanian Retrospective Study.新冠病毒疾病导致慢性自发性荨麻疹病情加重：一项罗马尼亚的回顾性研究。
Healthcare (Basel). 2021 Sep 1;9(9):1144. doi: 10.3390/healthcare9091144.
本文引用的文献
1
COVID-19-related cutaneous manifestations associated with multiple drug sensitization as shown by lymphocyte transformation test.淋巴细胞转化试验显示与多种药物致敏相关的新型冠状病毒肺炎相关皮肤表现。
J Eur Acad Dermatol Venereol. 2020 Dec;34(12):e779-e781. doi: 10.1111/jdv.16878. Epub 2020 Sep 7.
2
Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab.1例新型冠状病毒肺炎患者慢性自发性荨麻疹加重：对奥马珠单抗反应迅速且效果良好
Int J Dermatol. 2020 Oct;59(10):1294-1295. doi: 10.1111/ijd.15134. Epub 2020 Aug 17.
3
Acro-ischemic lesions associated with extremely elevated D-Dimer in a child during the COVID-19 pandemic.在新冠疫情期间，一名儿童出现与D - 二聚体极度升高相关的肢端缺血性病变。
Australas J Dermatol. 2021 Feb;62(1):80-82. doi: 10.1111/ajd.13424. Epub 2020 Aug 17.
4
Urticaria and COVID-19 infection: a critical appraisal.荨麻疹与新冠病毒感染：批判性评估
J Dermatolog Treat. 2022 May;33(3):1777. doi: 10.1080/09546634.2020.1808155. Epub 2020 Aug 19.
5
What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2?在 COVID-19 或 SARS-CoV-2 无症状感染期间，皮肤科医生应该了解哪些与肥大细胞、树突状细胞、荨麻疹和奥马珠单抗相关的知识？
Dermatol Ther. 2020 Nov;33(6):e14068. doi: 10.1111/dth.14068. Epub 2020 Aug 13.
6
Enanthem in Patients With COVID-19 and Skin Rash.COVID-19 患者的口咽部黏膜疹和皮疹。
JAMA Dermatol. 2020 Oct 1;156(10):1134-1136. doi: 10.1001/jamadermatol.2020.2550.
7
Urticaria in the times of COVID-19.新冠疫情时期的荨麻疹
Dermatol Ther. 2020 Nov;33(6):e13817. doi: 10.1111/dth.13817. Epub 2020 Jul 7.
8
Omalizumab and COVID-19 treatment: Could it help?奥马珠单抗与新冠病毒病治疗：它会有帮助吗？
Dermatol Ther. 2020 Jul;33(4):e13792. doi: 10.1111/dth.13792. Epub 2020 Jul 13.
9
The clinics of HHV-6 infection in COVID-19 pandemic: Pityriasis rosea and Kawasaki disease.HHV-6 感染在 COVID-19 大流行中的临床特征：玫瑰糠疹和川崎病。
Dermatol Ther. 2020 Jul;33(4):e13730. doi: 10.1111/dth.13730. Epub 2020 Jun 29.
10
Long-term follow-up effect of omalizumab in chronic spontaneous urticaria and its association with serum C-reactive protein levels.奥马珠单抗治疗慢性自发性荨麻疹的长期随访效果及其与血清C反应蛋白水平的关系
Dermatol Ther. 2020 Jul;33(4):e13663. doi: 10.1111/dth.13663. Epub 2020 Jun 26.
Zotero 插件